Cellectar Biosciences (CLRB)
NASDAQ:CLRB
Want to see CLRB full AI Analyst Report?
CLRB Stock Chart & Stats
$3.29
-$0.03(-9.33%)
At close: 4:00 PM EST
$3.29
-$0.03(-9.33%)
Day’s Range― - ―
52-Week Range$2.43 - $20.61
Previous CloseN/A
Volume1.30M
Average Volume (3M)105.19K
Market Cap
$11.41M
Enterprise Value-$4.62M
Total Cash (Recent Filing)$13.20M
Total Debt (Recent Filing)$409.59K
Price to Earnings (P/E)―
Beta1.09
Next Earnings
May 12, 2026EPS Estimate
-1.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.65
Shares Outstanding4,240,129
10 Day Avg. Volume157,484
30 Day Avg. Volume105,193
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.78
Price to Sales (P/S)0.00
P/FCF Ratio-0.33
Enterprise Value/Market Cap-0.40
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit45.38
Enterprise Value/Ebitda0.21
Forecast
1Y Price Target
$12.00Price Target Upside264.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-5.54
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development MomentumFirst patient enrollment in the CLR-125 early-stage trial demonstrates tangible clinical progress for the program and advances the path toward meaningful efficacy readouts.
Drug-delivery Platform ValidationStructural identity between CLR-125 and a prior radioconjugate with prior clinical activity supports validation of the drug-delivery platform and bolsters scientific confidence in the approach.
Imaging And Dosimetry-driven DosingInclusion of imaging and dosimetry in the trial design can confirm tumor targeting and inform dosing decisions, strengthening confidence in both safety and potential therapeutic activity.
Bears Say
Development And Regulatory UncertaintyCommercialization hinges on positive trial results and regulatory approvals, which introduces significant development and regulatory uncertainty for the investment case.
Financing And Shareholder Dilution RiskConfirmatory trials and regulatory filings are likely to require additional capital, creating the prospect of fundraising that could dilute existing shareholders.
Cellectar Biosciences News
CLRB FAQ
What was Cellectar Biosciences’s price range in the past 12 months?
Cellectar Biosciences lowest stock price was $2.43 and its highest was $20.61 in the past 12 months.
What is Cellectar Biosciences’s market cap?
Cellectar Biosciences’s market cap is $11.41M.
When is Cellectar Biosciences’s upcoming earnings report date?
Cellectar Biosciences’s upcoming earnings report date is May 12, 2026 which is in 9 days.
How were Cellectar Biosciences’s earnings last quarter?
Cellectar Biosciences released its earnings results on Mar 04, 2026. The company reported $0.65 earnings per share for the quarter, beating the consensus estimate of -$1.225 by $1.875.
Is Cellectar Biosciences overvalued?
According to Wall Street analysts Cellectar Biosciences’s price is currently Undervalued.
Does Cellectar Biosciences pay dividends?
Cellectar Biosciences does not currently pay dividends.
What is Cellectar Biosciences’s EPS estimate?
Cellectar Biosciences’s EPS estimate is -1.89.
How many shares outstanding does Cellectar Biosciences have?
Cellectar Biosciences has 4,240,129 shares outstanding.
What happened to Cellectar Biosciences’s price movement after its last earnings report?
Cellectar Biosciences reported an EPS of $0.65 in its last earnings report, beating expectations of -$1.225. Following the earnings report the stock price went up 8.209%.
Which hedge fund is a major shareholder of Cellectar Biosciences?
Currently, no hedge funds are holding shares in CLRB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectar Biosciences
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
CLRB Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call emphasized significant strategic and clinical progress—regulatory alignment with EMA, Breakthrough/PRIME designations, full 12‑month follow-up on the pivotal dataset, initiation of CLR125 Phase 1b, strengthened IP and isotope supply, and material reductions in operating expenses that improved the company’s net loss profile. Offsetting these positives are a constrained cash position (cash runway only into 2026), the need for additional capital to initiate certain programs (notably CLR225) and execute confirmatory trials, reliance on enrollment and regulatory timing for near‑term milestones, and a substantial drop in other (non‑cash) income. Overall, the company made meaningful de‑risking and value-creation moves but faces near-term financing and execution risks.View all CLRB earnings summariesCLRB Stock 12 Month Forecast
Average Price Target
$12.00
▲(264.74% Upside)
Technical Analysis
Ownership Overview
0.73% Insiders
2.51% Mutual Funds
4.00% Other Institutional Investors
90.84% Public Companies and
Individual Investors